Zepbound vs Ozempic: Cost and Access Head-to-Head

What Are Zepbound and Ozempic, and How Do They Differ Mechanistically?

Zepbound and Ozempic share a once-weekly injection schedule but work through different receptors. Zepbound (tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Ozempic (semaglutide) targets the GLP-1 receptor only. That extra GIP action is likely why tirzepatide produces larger weight reductions across trials.

Tirzepatide: Dual Incretin Action

The GIP receptor component of tirzepatide appears to amplify the appetite-suppressing and metabolic effects already seen with GLP-1 agonism alone. In a 2022 mechanistic review published in Diabetes Care, dual incretin agonism was described as a strategy capable of producing additive effects on insulin secretion, glucagon suppression, and energy intake reduction [1].

Tirzepatide's half-life is approximately five days, supporting weekly dosing. The drug is available in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg [2].

Semaglutide: Selective GLP-1 Agonism

Ozempic uses a C-18 fatty diacid chain to extend the half-life of semaglutide to roughly one week, making once-weekly dosing feasible. Approved doses in the Ozempic formulation are 0.5 mg, 1 mg, and 2 mg. The FDA prescribing information for Ozempic specifies that the 2 mg dose is indicated for additional glycemic control in adults with type 2 diabetes who need more A1C reduction after 0.5 or 1 mg [3].

Efficacy: What Do the Clinical Trials Actually Show?

No published head-to-head randomized controlled trial has directly compared Zepbound to Ozempic in the same population. Comparisons here draw on separate key trials using different study populations, so absolute numbers should not be treated as equivalent.

SURMOUNT-1 (Tirzepatide for Obesity)

SURMOUNT-1 enrolled 2,539 adults without diabetes who had a BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity. At 72 weeks, tirzepatide 15 mg produced a mean body-weight reduction of 20.9% versus 3.1% with placebo. Tirzepatide 10 mg produced 19.5% weight loss, and 5 mg produced 15.0% [4]. These results were published in the New England Journal of Medicine in 2022.

Roughly 37% of participants receiving tirzepatide 15 mg lost 25% or more of their body weight, a benchmark rarely reached with older agents [4].

SUSTAIN-7 (Semaglutide vs. Dulaglutide in T2D)

SUSTAIN-7 compared semaglutide 0.5 mg and 1 mg against dulaglutide 0.75 mg and 1.5 mg over 40 weeks in 1,201 adults with type 2 diabetes. Semaglutide 1 mg produced a mean weight loss of 5.5 kg compared with 2.3 kg for dulaglutide 0.75 mg. Semaglutide 1 mg also reduced HbA1c by 1.5% versus 1.1% with dulaglutide 0.75 mg [5]. Full data are available at PubMed PMID 29395633.

The SUSTAIN-7 population had established T2D, making a direct weight-loss comparison to SURMOUNT-1 (which excluded diabetes) statistically invalid. Semaglutide's weight loss in the diabetes setting is generally lower than in the obesity-only setting.

What About Semaglutide at Higher Doses?

Wegovy, not Ozempic, is the 2.4 mg weekly semaglutide formulation approved for chronic weight management. STEP-1 (N=1,961) showed 14.9% mean weight loss at 68 weeks with semaglutide 2.4 mg versus 2.4% placebo, published in the New England Journal of Medicine in 2021 [6]. This article compares Ozempic specifically (max 2 mg), not Wegovy.

FDA Approvals and Labeled Indications

Zepbound received FDA approval in November 2023 for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related condition such as hypertension, dyslipidemia, or type 2 diabetes [2].

Ozempic holds FDA approval for glycemic control in adults with type 2 diabetes and for reducing major adverse cardiovascular events in adults with T2D and established cardiovascular disease [3]. Weight loss is a well-documented side effect of Ozempic, but the drug is not labeled by the FDA for weight management.

This distinction matters enormously for insurance coverage.

Off-Label Use and Prescribing Patterns

Physicians may prescribe Ozempic off-label for weight loss, and many do. The FDA's guidance on off-label use confirms this is legally permissible, but insurers are under no obligation to cover off-label prescriptions [7]. Patients who receive Ozempic purely for weight loss without a T2D diagnosis face a much steeper uphill battle with prior authorizations.

Cost: List Price vs. What Patients Actually Pay

Wholesale Acquisition Cost

As of mid-2024, the list (wholesale acquisition) price for both Zepbound and Ozempic sits near $1,000 per month in the United States. Eli Lilly set Zepbound's list price at approximately $1,059.87 per month for the maintenance doses. Novo Nordisk's Ozempic carries a similar list price of roughly $936 per month for the 2 mg dose pen.

Neither figure reflects what most commercially insured patients pay. According to data from the CDC's 2023 National Health Interview Survey, out-of-pocket drug costs are a primary reason adults with obesity do not fill GLP-1 prescriptions [8].

Manufacturer Savings Programs

Eli Lilly offers the Zepbound Savings Card, which may reduce monthly costs to as low as $550 for eligible commercially insured patients and to $25 for patients who meet income and insurance criteria. The full terms are posted at Lilly's savings portal and eligibility excludes patients on Medicare, Medicaid, or other federal programs [2].

Novo Nordisk offers a similar savings card for Ozempic, potentially reducing costs to around $99 per month for eligible commercially insured patients. Again, federal insurance beneficiaries are excluded.

Medicare and Medicaid Coverage

Medicare Part D currently does not cover drugs prescribed solely for weight loss under the Consolidated Appropriations Act. Ozempic may be covered under Part D for T2D management, while Zepbound coverage under Medicare for obesity remains limited unless the TREAT Act or similar legislation passes [9]. The CMS coverage database reflects current formulary policies for federally sponsored plans.

Medicaid coverage varies by state. A handful of states have added GLP-1 agonists for obesity to their preferred drug lists, but most have not.

Compounded Tirzepatide and Semaglutide: A Cost Caveat

During the FDA shortage period (2022 to 2024), compounded versions of both semaglutide and tirzepatide became widely available at substantially lower prices, sometimes $200, $400 per month. The FDA's drug shortage database tracks the status of these shortages. Compounded drugs are not FDA-approved and carry variable quality assurance risks; the FDA issued a safety communication in 2023 warning about compounded tirzepatide specifically [10].

Insurance Access: Prior Authorization and Coverage Criteria

Zepbound Coverage for Obesity

Because Zepbound carries an FDA obesity indication, it qualifies for coverage under commercial plans that include anti-obesity medications on their formularies. The American Heart Association's 2023 obesity management statement called for broader payer coverage of evidence-based anti-obesity medications, noting that coverage gaps are not driven by efficacy data [11].

Typical commercial prior-authorization criteria for Zepbound require a BMI of 30 or higher (or 27 or higher with comorbidity), documentation of a prior 3 to 6 month lifestyle intervention, and in some cases a trial of an older anti-obesity medication [2].

Ozempic Coverage for Diabetes vs. Weight Loss

Ozempic's T2D indication means coverage for patients with that diagnosis is comparatively straightforward. Most commercial formularies and virtually all Medicare Part D plans cover Ozempic at some tier for patients with documented T2D and an A1C above a threshold (usually 7.5% or 8%).

For patients who want Ozempic for weight loss only, prior authorization is nearly always denied because the labeled indication is T2D management, not obesity. Clinicians at HealthRX note that switching from an off-label Ozempic prescription to an on-label Zepbound prescription sometimes resolves coverage problems for eligible patients.

The table below summarizes the coverage logic:

| Situation | Zepbound | Ozempic | |---|---|---| | T2D, A1C above 7.5% | May be covered; PA often required | Usually covered; PA often required | | Obesity only, BMI 30+ | Covered on many commercial plans with PA | Rarely covered; off-label denial likely | | Medicare Part D | Limited; depends on plan and indication | Covered for T2D; not for weight loss | | Medicaid | State-dependent | State-dependent, more often covered for T2D | | No insurance | ~$1,059/month list; savings card available | ~$936/month list; savings card available |

Side-Effect Profile: Similarities and Key Differences

Both drugs produce predominantly gastrointestinal side effects during dose escalation, including nausea, vomiting, diarrhea, and constipation. In SURMOUNT-1, nausea occurred in 31.0% of the tirzepatide 15 mg group versus 11.5% of placebo participants [4]. Vomiting occurred in 20.4% versus 4.5%, respectively.

Pancreatitis and Thyroid Warnings

Both tirzepatide and semaglutide carry class-level FDA boxed warnings regarding the potential risk of thyroid C-cell tumors, observed in rodent studies. Neither drug is recommended for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [2, 3].

Acute pancreatitis has been reported with GLP-1 receptor agonists as a class. The FDA MedWatch system continues to collect post-market data on both agents [7].

Cardiovascular Safety

Ozempic has published SUSTAIN-6 cardiovascular outcomes data showing a significant reduction in the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (hazard ratio 0.74; 95% CI 0.58 to 0.95; P<0.001 for noninferiority), published in the New England Journal of Medicine in 2016 [12]. This CV outcomes evidence gives Ozempic a label advantage for high-CV-risk diabetic patients.

Zepbound's dedicated cardiovascular outcomes trial, SURPASS-CVOT, was completed but results were pending peer-reviewed publication as of this writing. A 2024 preprint suggested benefit, but the HealthRX medical team recommends waiting for the full publication before drawing equivalence conclusions.

How to Choose: A Clinical Decision Summary

For Patients With Type 2 Diabetes

If the primary goal is glycemic control with secondary weight loss, Ozempic is typically the first-line choice: it carries a T2D label, has established CV outcomes data from SUSTAIN-6, and is covered by most commercial and Medicare Part D plans. Tirzepatide (as Mounjaro, not Zepbound) also has an FDA T2D indication and produced greater A1C reductions in the SURPASS-2 trial, published in the New England Journal of Medicine in 2021 [13]. Clinicians should compare both for a T2D patient who also has substantial excess weight.

For Patients Seeking Weight Management

For patients whose primary goal is weight loss without T2D, Zepbound's labeled obesity indication gives it an insurance-access advantage over Ozempic. The 20.9% mean weight loss at 72 weeks in SURMOUNT-1 [4] also exceeds what Ozempic's approved doses are expected to produce based on SUSTAIN trial data.

The Endocrine Society's 2023 Clinical Practice Guideline on Obesity Pharmacotherapy recommends selecting agents based on comorbidities, efficacy data, tolerability, cost, and insurance coverage rather than on any single metric [14].

Out-of-Pocket Cost Considerations

For uninsured patients who are not Medicare/Medicaid beneficiaries, the savings cards from each manufacturer bring costs close to each other. The choice then depends primarily on efficacy goals and tolerability. A patient who did not tolerate nausea at semaglutide 1 mg may not tolerate tirzepatide either, but the dose-escalation schedule for Zepbound (starting at 2.5 mg for four weeks) may allow more gradual adaptation.

Switching Between Zepbound and Ozempic

Patients switching from Ozempic to Zepbound should restart at the lowest tirzepatide dose (2.5 mg weekly) regardless of the semaglutide dose they were receiving, per standard clinical practice. No published crossover pharmacokinetic study has defined a conversion table between the two agents. The American Association of Clinical Endocrinology (AACE) obesity guidelines advise clinicians to treat the transition as a new initiation and monitor patients closely during the first four to eight weeks [15].

The reverse switch, from Zepbound back to Ozempic, is less commonly needed but may occur when insurance coverage changes. The same principle applies: restart Ozempic at 0.25 mg weekly for four weeks, then titrate according to tolerability and glycemic or weight response.